Surface Oncology Inc (NASDAQ:SURF) announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022.
- Pharmacokinetics (PK) from the dose-escalation phase of the SRF388 Phase 1 study were linear, with no dose-limiting toxicities reported.
- The concentration of SRF388 associated with optimal antitumor activity in a preclinical mouse model was approximately 20-fold above the concentration needed to inhibit whole blood phosphorylated STAT1 completely.
- The concentration of SRF388 was reached and exceeded in patients at a 10 mg/kg dose. One patient with squamous non-small-cell lung cancer experienced a confirmed partial response at this dose.
- SRF388 translational data supports the recommended Phase 2 monotherapy dose selection of 10 mg/kg administered intravenously every four weeks.
- The efficacy of adding IL-27 blockade with SRF388 to atezolizumab/bevacizumab in treatment-naïve HCC is also being explored in a Phase 2 study.
- Price Action: SURF shares are down 2.17% at $2.71 during the market session on the last check Monday.
